<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1911246263
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Salitav
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TOLVAPTAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        3642.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jazeera Pharmaceutical Industries (JPI)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)	
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C03XA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Salitav, which contains the active substance tolvaptan, belongs to a group of medicines called vasopressin antagonists. Vasopressin is a hormone that helps prevent the loss of water from the body by reducing urine output. Antagonist means that it prevents vasopressin having its effect on water retention. This leads to a reduction in the amount of water in the body by increasing urine production and as a result it increases the level or concentration of sodium in your blood.</p><p>Salitav is used to treat low serum sodium levels in adults. You have been prescribed this medicine because you have a lowered sodium level in your blood as a result of a disease called &ldquo;syndrome of inappropriate antidiuretic hormone secretion&rdquo; (SIADH) where the kidneys retain too much water. This disease causes an inappropriate production of the hormone vasopressin which has caused the sodium levels in your blood to get too low (hyponatremia). That can lead to difficulties in concentration and memory, or in keeping your balance.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Salitav </strong></p><ul><li>If you are allergic to tolvaptan or any of the other ingredients of this medicine (listed in section 6) or if you are allergic to benzazepine or benzazepine derivatives (e.g., benazepril, conivaptan, fenoldopam mesylate or mirtazapine)</li><li>If your kidneys do not work (no urine production)</li><li>If you have a condition which increases the salt in your blood (&ldquo;hypernatremia&rdquo;)</li><li>If you have a condition which is associated with a very low blood volume</li><li>If you do not realise when you are thirsty</li><li>If you are pregnant</li><li>If you are breast-feeding.</li></ul><p><strong>Warnings and precautions</strong><br />Talk to your doctor or pharmacist before taking Salitav:</p><ul><li>If you cannot drink enough water or if you are fluid restricted</li><li>If you have difficulties in urination or have an enlarged prostate</li><li>If you suffer from liver disease</li><li>If you had an allergic reaction in the past to benzazepine, tolvaptan or other benzazepine derivatives (e.g., benazepril, conivaptan, fenoldopam mesylate or mirtazapine), or to any of the other ingredients of this medicine (listed in section 6).</li><li>If you suffer from a kidney disease called autosomal dominant polycystic kidney disease (ADPKD)</li><li>If you have diabetes.</li></ul><p><em>Drinking enough water</em><br />Tolvaptan causes water loss because it increases your urine production. This water loss may result in side effects such as dry mouth and thirst or even more severe side effects like kidney problems (see section 4). It is therefore important that you have access to water and that you are able to drink sufficient amounts when you feel thirsty.</p><p><strong>Children and adolescents</strong><br />Salitav is not suitable for children and adolescents (under age 18).</p><p><strong>Other medicines and Salitav</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes all medicines obtained without a prescription.</p><p>The following medicines may increase the effect of this medicine:</p><ul><li>Ketoconazole (against fungal infections),</li><li>Macrolide antibiotics,</li><li>Diltiazem (treatment for high blood pressure and chest pain),</li><li>Other products which increase the salt in your blood or which contain large amounts of salt.</li></ul><p>The following medicines may lower the effect of this medicine:</p><ul><li>Barbiturates (used to treat epilepsy/seizures and some sleep disorders),</li><li>Rifampicin (against tuberculosis).</li></ul><p>This medicine may increase the effect of the following medicines:</p><ul><li>Digoxin (used for treatment of irregularities of heartbeat and heart failure),</li><li>Dabigatran etexilate (used to thin the blood),</li><li>Metformin (used to treat diabetes),</li><li>Sulfasalazine (used to treat inflammatory bowel disease or rheumatoid arthritis).</li></ul><p>This medicine may lower the effect of the following medicines:</p><ul><li>Desmopressin (used to increase blood clotting factors).</li></ul><p>It may still be alright for you to take these medicines and Salitav together. Your doctor will be able to decide what is suitable for you.</p><p><strong>Salitav with food and drink</strong><br />Avoid drinking grapefruit juice when taking Salitav.</p><p><strong>Pregnancy and breast-feeding</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>Do not take this medicine if you are pregnant or breast-feeding.</p><p>Adequate contraceptive measures must be used during use of this medicine.</p><p><strong>Driving and using machines</strong><br />Tolvaptan is unlikely to adversely affect your ability to drive or to operate machinery. However, you may occasionally feel dizzy or weak or you may faint for a short period.</p><p><strong>Salitav contains lactose and sodium</strong><br />Salitav contains lactose. Each tablet of Salitav 15 mg and 30 mg Tablets contains 28 mg or 56 mg lactose; respectively. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p>Salitav contains sodium. Each tablet of Salitav 15 mg and 30 mg Tablets contains 0.46 mg or 0.91 mg sodium; respectively. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><ul><li>Treatment with tolvaptan will be initiated in hospital.</li><li>For treatment of your low sodium (hyponatremia), your doctor will start with a dose of 15 mg and may then increase it to a maximum of 60 mg to achieve the desired level of serum sodium. To monitor the effects of tolvaptan your doctor will do regular blood tests. To achieve the desired level of serum sodium your doctor can give in some instances a lower dose of 7.5 mg.</li><li>Swallow the tablet without chewing, with a glass of water.</li><li>Take the tablets once a day preferably in the morning with or without food.</li></ul><p><strong>If you take more Salitav than you should</strong><br />If you have taken more tablets than your prescribed dose, drink plenty of water and contact your doctor or your local hospital immediately. Remember to take the medicine pack with you so that it is clear what you have taken.</p><p><strong>If you forget to take Salitav</strong><br />If you forget to take your medicine, you have to take the dose as soon as you remember on the same day. If you do not take your tablet on one day, take your normal dose on the next day. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking Salitav</strong><br />If you stop taking Salitav this may lead to reoccurrence of your low sodium. Therefore, you should only stop taking Salitav if you notice side effects requiring urgent medical attention (see section 4) or if your doctor tells you to.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong><em>If you notice any of the following side effects, you may need urgent medical attention. Stop taking tolvaptan and immediately contact a doctor or go to the nearest hospital if you: </em></strong></p><ul><li>Find it difficult to urinate</li><li>Find a swelling of the face, lips or tongue, itching, generalised rash, or severe wheezing or breathlessness (symptoms of an allergic reaction).</li></ul><p>Consult your doctor if symptoms of fatigue, loss of appetite, right upper abdominal discomfort, dark urine or jaundice (yellowing of skin or eyes) occur.</p><p><strong><em>Other side effects</em></strong><br /><strong>Very common (may affect more than 1 in 10 people) </strong></p><ul><li>Feeling sick</li><li>Thirst</li><li>Rapid rise in level of sodium.</li></ul><p><strong>Common (may affect up to 1 in 10 people) </strong></p><ul><li>Excessive drinking of water</li><li>Water loss</li><li>High levels of sodium, potassium, creatinine, uric acid and blood sugar</li><li>Decrease in level of blood sugar</li><li>Decreased appetite</li><li>Fainting</li><li>Headache</li><li>Dizziness</li><li>Low blood pressure when standing up</li><li>Constipation</li><li>Diarrhoea</li><li>Dry mouth</li><li>Patchy bleeding in the skin</li><li>Itching</li><li>Increased need to urinate, or to urinate more frequently</li><li>Tiredness, general weakness</li><li>Fever</li><li>General feeling of being unwell</li><li>Blood in urine</li><li>Raised levels of liver enzymes in the blood</li><li>Raised levels of creatinine in the blood.</li></ul><p><strong>&nbsp;Uncommon (may affect up to 1 in 100 people) </strong></p><ul><li>Sense of taste altered</li><li>Kidney problems</li></ul><p><strong>&nbsp;Not known (cannot be estimated from the available data) </strong></p><ul><li>Allergic reactions (see above)</li><li>Liver problems</li><li>Acute liver failure (ALF)</li><li>Increase in liver enzymes.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from light and moisture.</p><p>Do not use this medicine after the expiry date which is stated on the outer package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is tolvaptan.</p><p>Each tablet of Salitav 15 mg and 30 mg Tablets contains 15 mg or 30 mg tolvaptan; respectively.</p><p>The other ingredients are hypromellose, lactose, microcrystalline cellulose, croscarmellose sodium, maize starch, colloidal silicone dioxide, magnesium stearate, FD&amp;C blue and sodium lauryl sulfate.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Salitav 15 mg Tablets are blue colored, round, biconvex tablets debossed with “T15” on one side and plain on the other side in PVC/Aclar-aluminum blisters.

Salitav 30 mg Tablets are blue colored, oval, biconvex tablets debossed with “T30” on one side and plain on the other side in PVC/Aclar-aluminum blisters.

Pack size: 10 Tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder, Bulk manufacturer and Batch releaser</strong><br />Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. Box 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><p>&bull; United Arab of Emirates<br />Pharmacovigilance &amp; Medical Device Section<br />P.O. Box: 1853<br />Tel: 80011111<br />Email: pv@ede.gov.ae<br />Drug Department<br />Ministry of Health &amp; Prevention<br />Dubai</p><p>&bull; Saudi Arabia<br />The National Pharmacovigilance Centre (NPC)<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa<br />&bull; Other GCC States<br />Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 12/2024; version number SA2.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي ساليتاف، المحتوي على المادة الفعّالة تولفابتان، إلى مجموعة أدوية تسمى مضادات فازوبريسين. فازوبريسين هو هرمون يساعد على منع فقدان الماء من الجسم بخفض إنتاج البول. تعني كلمة مضاد أنه يمنع تأثير الفازوبريسين على الاحتفاظ بالماء. يؤدي ذلك إلى خفض كمية الماء في الجسم عن طريق زيادة إنتاج البول؛ ونتيجة لذلك فإنه يزيد من مستوى أو تركيز الصوديوم في الدم.</p><p>يستخدم ساليتاف لعلاج انخفاض مستويات الصوديوم في الدم لدى البالغين. لقد تم وصف هذا الدواء لك لأنك تعاني من انخفاض مستوى الصوديوم في دمك نتيجة لمرض يسمى &quot;متلازمة الإفراز غير الملائم للهرمون المضاد لإدرار البول&quot;، حيث تحتفظ الكليتان بالكثير من الماء. يتسبب هذا المرض في إنتاج غير ملائم لهرمون فازوبريسين الذي تسبب في انخفاض شديد لمستويات الصوديوم في دمك (نقص صوديوم الدم). يمكن أن يؤدي ذلك إلى صعوبات في التركيز والذاكرة، أو في الحفاظ على توازنك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول ساليتاف </strong></p><ul dir="rtl"><li>إذا كنت تعاني من حساسية لتولفابتان أو أي من المكونات الأخرى المستخدمة في تركيبة هذا الدواء (المذكورة في القسم 6) أو إذا كنت تعاني من حساسية لبنزازيبين أو مشتقاته (مثل بينازيبريل أو كونيفابتان ميسيلات الفينولدوبام أو ميرتازابين)</li><li>إذا كانت كليتاك لا تعملان (لا تدران البول)</li><li>إذا كنت تعاني من حالة تسبب زيادة نسبة الصوديوم في دمك (&quot;فرط صوديوم الدم&quot;)</li><li>إذا كنت تعاني من حالة مرتبطة بانخفاض كبير في حجم الدم</li><li>إذا كنت لا تدرك عندما تكون تشعر بالعطش</li><li>إذا كنتِ حاملاً</li><li>إذا كنتِ ترضعين طبيعياً.</li></ul><p><strong>&nbsp;الاحتياطات والتحذيرات&nbsp;</strong><br />تحدث مع طبيبك أو الصيدلي قبل تناول ساليتاف:</p><ul dir="rtl"><li>إذا كنت لا تستطيع شرب كمية كافية من الماء أو إذا كانت عليك قيود في استهلاك السوائل</li><li>إذا كنت تواجه صعوبات في التبول أو تضخم البروستاتا</li><li>إذا كنت تعاني من مرض في الكبد</li><li>إذا سبق أن عانيت من رد فعل تحسسي لبنزازيبين، تولفابتان أو مشتقات بنزازيبين الأخرى (مثل بينازيبريل، كونيفابتان، ميسيلات الفينولدوبام أو ميرتازابين) أو لأي من المواد الأخرى المستخدمة في تركيبة هذا الدواء (المذكورة في القسم 6).</li><li>إذا كنت تعاني من مرض كلوي يسمى داء الكلى متعددة الأكياس الجسدي السائد الوراثي.</li><li>إذا كنت مصاباً بمرض السكري.</li></ul><p><em>شرب كمية كافية من المياه&nbsp;</em><br />تتسبب مادة تولفابتان في فقدان المياه لأنها تزيد من إنتاج البول لديك. قد يؤدي فقدان الماء هذا إلى حدوث آثار جانبية مثل جفاف الفم والعطش أو حتى آثار جانبية أكثر حدة مثل مشاكل الكلية (انظر القسم 4). لذلك من المهم أن تحصل على مياه وأن تتمكن من شرب الكميات الكافية عندما تشعر بالعطش.</p><p>&nbsp;<strong>الأطفال والمراهقون&nbsp;</strong><br />ساليتاف غير مناسب للأطفال والمراهقين (أقل من 18 عاماً).</p><p>&nbsp;<strong>الأدوية الأخرى وساليتاف&nbsp;</strong><br />أخبر طبيبك أو الصيدلي إذا كنت تتناول، تناولت مؤخراً، أو قد تتناول أية أدوية أخرى. ويشمل ذلك الأدوية التي تتناولها بدون وصفة طبية.</p><p>&nbsp;قد تزيد الأدوية التالية من التأثير الذي يحدثه هذا الدواء:</p><ul dir="rtl"><li>كيتوكونازول (مضاد لحالات العدوى الفطرية)،</li><li>المضادات الحيوية من فئة الماكرولايد،</li><li>ديلتيازيم (علاج ارتفاع ضغط الدم وألم الصدر)،</li><li>المستحضرات الأخرى التي تزيد الملح في دمك أو التي تحتوي على كميات كبيرة من الملح.</li></ul><p>قد تقلل الأدوية التالية من التأثير الذي يحدثه هذا الدواء:</p><ul dir="rtl"><li>الباربيتورات (تستخدم لعلاج الصرع/النوبات وبعض اضطرابات النوم)،</li><li>ريفامبيسين (لعلاج السل).</li></ul><p>قد يزيد هذا الدواء تأثير الأدوية التالية:</p><ul dir="rtl"><li>ديجوكسين (يستخدم لعلاج حالات عدم انتظام نبضات القلب وفشل القلب)،</li><li>إتكسيلات الدابيجاتران (يستخدم لترقيق الدم)،</li><li>ميتفورمين (يستخدم لعلاج مرض السكري)،</li><li>سلفاسالازين (يستخدم لعلاج مرض التهاب الأمعاء أو التهاب المفاصل الروماتويدي).</li></ul><p>قد يقلل هذا الدواء من تأثير الأدوية التالية:</p><ul dir="rtl"><li>ديزموبريسين (يستخدم لزيادة عوامل تخثر الدم).</li></ul><p>قد لا يزال من المناسب لك تناول هذه الأدوية مع ساليتاف. سيكون طبيبك قادراً على تحديد ما هو مناسب لحالتك.</p><p><strong>ساليتاف مع الطعام والشراب&nbsp;</strong><br />تجنب شرب عصير الجريب فروت عند تناول ساليتاف.</p><p>&nbsp;<strong>الحمل والرضاعة&nbsp;</strong><br />استشيري طبيبك أو الصيدلي قبل تناول هذا الدواء إذا كنت حاملاً أو مرضعاً، تعتقدين بأنك حامل أو تخططين لذلك.</p><p>لا تتناولي هذا الدواء إذا كنتِ حاملاً أو مرضعاً.</p><p>يجب استخدام وسائل منع الحمل المناسبة أثناء استخدام هذا الدواء.</p><p><strong>القيادة واستخدام الآلات&nbsp;</strong><br />لا يُرجح أن يؤثر تولفابتان سلباً على قدرتك على القيادة أو تشغيل الآلات. ومع ذلك، قد تشعر أحياناً بالدوخة أو الضعف أو تتعرض للإغماء لفترة قصيرة.</p><p dir="RTL"><strong>يحتوي ساليتاف</strong> <strong>على</strong><strong> اللاكتوز والصوديوم&nbsp;</strong><br />يحتوي ساليتاف على اللاكتوز. يحتوي كل قرص من ساليتاف 15 ملغم و30 ملغم أقراص على 28 ملغم أو 56 ملغم لاكتوز؛ على التوالي. إذا أخبرك طبيبك بأن لديك عدم تحمل لبعض السكريات، تواصل مع طبيبك قبل تناول هذا المستحضر الدوائي.</p><p dir="RTL">يحتوي<strong> </strong>ساليتاف على الصوديوم. يحتوي كل قرص من ساليتاف 15 ملغم و30 ملغم أقراص على 0,46 ملغم أو 0,91 ملغم صوديوم؛ على التوالي. يحتوي هذا الدواء على أقل من 1 ملمول صوديوم (23 ملغم) لكل قرص، بمعنى أنه &rsquo;خال من الصوديوم&lsquo; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قم دائماً بتناول هذا الدواء كما أخبرك طبيبك أو الصيدلي تماماً. تحقق من طبيبك أو الصيدلي إذا لم تكن متأكدًا.</p><ul dir="rtl"><li>سيبدأ العلاج بتولفابتان في المستشفى.</li><li>لعلاج انخفاض مستوى الصوديوم لديك (نقص صوديوم الدم)، سيبدأ طبيبك بإعطاء جرعة 15 ملغم، وقد يزيدها بعد ذلك إلى 60 ملغم كحد أقصى؛ للوصول إلى المستوى المرغوب من الصوديوم في مصل الدم. سوف يجري لك طبيبك اختبارات دم منتظمة؛ لمتابعة تأثيرات تولفابتان. يمكن أن يعطيك طبيبك جرعة أقل من 7,5 ملغم في بعض الحالات؛ لتحقيق المستوى المرغوب من الصوديوم في الدم.</li><li>ابتلع القرص دون مضغه مع كوب من الماء.</li><li>تناول الأقراص مرة واحدة في اليوم ويفضل صباحاً مع الطعام أو بدونه.</li></ul><p dir="RTL"><strong>&nbsp;إذا تناولت ساليتاف أكثر من اللازم&nbsp;</strong><br />إذا تناولت أقراصاً تزيد عن جرعتك الموصوفة، اشرب الكثير من الماء واتصل بطبيبك أو المستشفى المحلي فوراً. تذكر أن تأخذ علبة الدواء معك حتى يتضح نوع الدواء الذي تناولته.</p><p><strong>إذا نسيت تناول ساليتاف&nbsp;</strong><br />إذا نسيت تناول دوائك، فعليك تناول الجرعة بمجرد أن تتذكرها في نفس اليوم. إذا لم تتناول القرص الموصوف لك في أحد الأيام، فتناول جرعتك العادية في اليوم التالي. لا تقم بتناول جرعة مضاعفة لتعويض الجرعة المنسية.</p><p><strong>إذا توقفت عن تناول ساليتاف&nbsp;</strong><br />إذا توقفت عن تناول ساليتاف، فقد يؤدي ذلك إلى تكرر حدوث انخفاض مستوى الصوديوم لديك. وعليه، يجب ألا تتوقف عن تناول ساليتاف إلا إذا لاحظت آثاراً جانبية تتطلب عناية طبية طارئة (انظر القسم 4) أو إذا أخبرك طبيبك بذلك.</p><p>إذا كانت لديك أي أسئلة إضافية حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبيةً، إلا إنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p><strong><em>إذا لاحظت أياً من الآثار الجانبية التالية، فقد تحتاج إلى تلقي العناية الطبية الطارئة. توقف عن تناول تولفابتان واتصل بطبيب فوراً أو توجه إلى أقرب مستشفى إذا كنت: </em></strong></p><ul dir="rtl"><li>تواجه مشكلة في التبول</li><li>تعاني من تورم في الوجه، الشفتين أو اللسان، حكة، طفح جلدي معمم أو صفير حاد أو ضيق في التنفس (أعراض رد فعل تحسسي).</li></ul><p>استشر طبيبك في حالة ظهور أعراض التعب، فقدان الشهية، عدم راحة في الجزء العلوي الأيمن من البطن، والبول الداكن أو اليرقان (اصفرار الجلد أو العينين).</p><p><strong><em>الآثار الجانبية الأخرى</em></strong><br /><strong>شائعة جداً (قد تؤثر على أكثر من شخص واحد من كل 10 أشخاص) </strong></p><ul dir="rtl"><li>غثيان</li><li>عطش</li><li>ارتفاع سريع في مستوى الصوديوم.</li></ul><p dir="RTL"><strong>شائعة (قد تؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص) </strong></p><ul dir="rtl"><li>الإفراط في شرب الماء</li><li>فقدان الماء</li><li>ارتفاع مستويات الصوديوم، البوتاسيوم، الكرياتينين، حمض اليوريك وسكر الدم</li><li>انخفاض مستوى سكر الدم</li><li>نقص الشهية</li><li>الإغماء</li><li>صداع</li><li>دوخة</li><li>انخفاض ضغط الدم عند الوقوف</li><li>إمساك</li><li>إسهال</li><li>جفاف الفم</li><li>نزف في أجزاء متفرقة من الجلد</li><li>حكة</li><li>زيادة الحاجة للتبول أو التبول بشكل متكرر</li><li>التعب، الضعف العام</li><li>حمّى</li><li>شعور عام بالتوعك</li><li>دم في البول</li><li>ارتفاع مستويات إنزيمات الكبد في الدم</li><li>مستويات مرتفعة للكرياتينين في الدم.</li></ul><p><strong>&nbsp;غير شائعة (قد تؤثر على ما يصل إلى شخص واحد من كل 100 شخص) </strong></p><ul dir="rtl"><li>تغير حاسة التذوق</li><li>مشاكل في الكلى<strong>&nbsp;</strong></li></ul><p dir="RTL"><strong>غير معروفة (لا يمكن تقديرها من البيانات المتاحة) </strong></p><ul dir="rtl"><li>ردود فعل تحسسية (انظر أعلاه)</li><li>مشاكل في الكبد</li><li>فشل كبدي حاد</li><li>ارتفاع في إنزيمات الكبد.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 30&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الضوء والرطوبة.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي تولفابتان.</p><p dir="RTL">يحتوي كل قرص من ساليتاف 15 ملغم و30 ملغم أقراص على 15 ملغم أو 30 ملغم تولفابتان؛ على التوالي.</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي هيبروميللوز، لاكتوز، سيلليلوز بلوري مكروي، كروسكارميللوز الصوديوم، نشا الذرة، ثاني أكسيد السيليكون الغروي، ستيرات المغنيسيوم، صبغة FD&amp;C زرقاء وكبريتات لوريل الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ساليتاف 15 ملغم أقراص هي أقراص زرقاء اللون، دائرية، محدبة الوجهين محفور عليها &quot;T15&quot; على جهة واحدة وملساء على الجهة الأخرى في أشرطة من كلوريد متعدد الڤينيل/أكلار-الألمنيوم.</p><p dir="RTL">ساليتاف 30 ملغم أقراص هي أقراص زرقاء اللون، بيضاوية، محدبة الوجهين محفور عليها &quot;T30&quot; على جهة واحدة وملساء على الجهة الأخرى في أشرطة من كلوريد متعدد الڤينيل/أكلار-الألمنيوم.</p><p dir="RTL">حجم العبوة: 10 أقراص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق</strong><strong>، </strong><strong>الشركة المصنعة لل</strong><strong>مستحضر النهائي ومحرر التشغيلة</strong><br />شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong><br />تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><p dir="RTL">&bull;&nbsp;الإمارات العربية المتحدة<br />قسم اليقظة الدوائية والجهاز الطبي<br />صندوق بريد: 1853<br />هاتف: 80011111<br />البريد الإلكتروني: &nbsp;pv@ede.gov.ae<br />إدارة الدواء<br />وزارة الصحة ووقاية المجتمع<br />دبي</p><p dir="RTL">&bull;&nbsp;المملكة العربية السعودية<br />المركز الوطني للتيقظ الدوائي<br />مركز الاتصال الموحد: 19999<br />البريد الإلكتروني: npc.drug@sfda.gov.sa<br />الموقع الإلكتروني: https://ade.sfda.gov.sa</p><p dir="RTL">&bull;&nbsp;دول الخليج العربي الأخرى<br />الرجاء الاتصال بالجهات الوطنية في كل دولة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 12/2024؛ رقم النسخة SA2.0.


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Salitav 15 mg Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet of Salitav 15 mg Tablets contains 15 mg tolvaptan.

Excipients with known effect: Lactose and sodium.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets.

Blue colored, round, biconvex tablets debossed with “T15” on one side and plain on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Salitav is indicated in adults for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Due to the need for a dose titration phase with close monitoring of serum sodium and volume status (see section 4.4), treatment with Salitav has to be initiated in hospital.</p><p><strong>&nbsp;Posology</strong><br />Tolvaptan has to be initiated at a dose of 15 mg once daily. The dose may be increased to a maximum of 60 mg once daily as tolerated to achieve the desired level of serum sodium.</p><p>For patients at risk of overly rapid correction of sodium e.g., patients with oncological conditions, very low baseline serum sodium, taking diuretics, or taking sodium supplementation a dose of 7.5 mg should be considered (see section 4.4).</p><p>During titration, patients must be monitored for serum sodium and volume status (see section 4.4). In case of inadequate improvement in serum sodium levels, other treatment options have to be considered, either in place of or in addition to tolvaptan. Use of tolvaptan in combination with other options may increase the risk of overly rapid correction of serum sodium (see sections 4.4 and 4.5). For patients with an appropriate increase in serum sodium, the underlying disease and serum sodium levels must be monitored at regular intervals to evaluate further need of tolvaptan treatment. In the setting of hyponatremia, the treatment duration is determined by the underlying disease and its treatment. Tolvaptan treatment is expected to last until the underlying disease is adequately treated or until such time that hyponatremia is no longer a clinical issue.</p><p>Tolvaptan must not be taken with grapefruit juice (see section 4.5).</p><p><strong>Special populations</strong><br /><u>Renal impairment</u><br />Tolvaptan is contraindicated in anuric patients (see section 4.3). Tolvaptan has not been studied in patients with severe renal failure. The efficacy and safety in this population is not well established.</p><p>Based on the data available, no dose adjustment is required in those with mild to moderate renal impairment.</p><p><u>Hepatic impairment</u><br />No information is available in patients with severe hepatic impairment (Child-Pugh class C). In these patients dosing has to be managed cautiously and electrolytes and volume status must be monitored (see section 4.4). No dose adjustment is needed in patients with mild or moderate hepatic impairment (Child-Pugh classes A and B).</p><p><u>Elderly</u><br />No dose adjustment is needed in elderly patients.</p><p><u>Paediatric population</u><br />The safety and efficacy of tolvaptan in children and adolescents under the age of 18 years have not yet been established. Tolvaptan is not recommended in the paediatric age group. &nbsp;</p><p><strong>Method of administration</strong><br />Oral use.</p><p>Administration preferably in the morning, without regard to meals. Tablets must be swallowed without chewing with a glass of water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 or to benzazepine or benzazepine derivatives (see section 4.4) 
• Anuria 
• Volume depletion 
• Hypovolemic hyponatremia 
• Hypernatremia 
• Patients who cannot perceive thirst 
• Pregnancy (see section 4.6) 
• Breast-feeding (see section 4.6)

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Urgent need to raise serum sodium acutely</strong><br />Tolvaptan has not been studied in a setting of urgent need to raise serum sodium acutely. For such patients, alternative treatment has to be considered.</p><p><strong>Access to water</strong><br />Tolvaptan may cause adverse reactions related to water loss such as thirst, dry mouth and dehydration (see section 4.8). Therefore, patients must have access to water and be able to drink sufficient amounts of water. If fluid restricted patients are treated with tolvaptan, extra caution has to be exercised to ensure that patients do not become overly dehydrated.</p><p><strong>Dehydration</strong><br />Volume status must be monitored in patients taking tolvaptan because treatment with tolvaptan may result in severe dehydration, which constitutes a risk factor for renal dysfunction. If dehydration becomes evident, take appropriate action which may include the need to interrupt or reduce the dose of tolvaptan and increase fluid intake.</p><p><strong>Urinary outflow obstruction</strong><br />Urinary output must be secured. Patients with partial obstruction of urinary outflow, for example patients with prostatic hypertrophy or impairment of micturition, have an increased risk of developing acute retention.</p><p><strong>Fluid and electrolyte balance</strong><br />Fluid and electrolyte status has to be monitored in all patients and particularly in those with renal and hepatic impairment. Administration of tolvaptan may cause too rapid increases in serum sodium (&ge; 12 mmol/L per 24 hours, please see below); therefore, monitoring of serum sodium in all patients must start no later than 4 to 6 hours after treatment initiation. During the first 1 to 2 days and until the tolvaptan dose is stabilised serum sodium and volume status must be monitored at least every 6 hours.</p><p><strong>Too rapid correction of serum sodium</strong><br />Patients with very low baseline serum sodium concentrations may be at greater risk for too rapid correction of serum sodium.</p><p>Too rapid correction of hyponatremia (increase &ge; 12 mmol/L/24 hours) can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma or death. Therefore, after initiation of treatment, patients have to be closely monitored for serum sodium and volume status (see above).</p><p>In order to minimise the risk of too rapid correction of hyponatremia the increase of serum sodium should be less than 10 mmol/L/24 hours to 12 mmol/L/24 hours and less than 18 mmol/L/48 hours. Therefore, more precautionary limits apply during the early treatment phase.</p><p>If sodium correction exceeds 6 mmol/L during the first 6 hours of administration or 8 mmol/L during the first 6 to 12 hours, respectively, the possibility that serum sodium correction may be overly rapid should be considered. These patients should be monitored more frequently regarding their serum sodium and administration of hypotonic fluid is recommended. In case serum sodium increases &ge; 12 mmol/L within 24 hours or &ge; 18 mmol/L within 48 hours, tolvaptan treatment is to be interrupted or discontinued followed by administration of hypotonic fluid.</p><p>In patients at higher risk of demyelination syndromes, for example those with hypoxia, alcoholism or malnutrition, the appropriate rate of sodium correction may be lower than that in patients without risk factors; these patients should be very carefully managed.</p><p>Patients who received other treatment for hyponatremia or medicinal products which increase serum sodium concentration (see section 4.5) prior to initiation of treatment with tolvaptan must be managed very cautiously. These patients may be at higher risk for developing rapid correction of serum sodium during the first 1 to 2 days of treatment due to potential additive effects.</p><p>Co-administration of Salitav with other treatments for hyponatremia, and medicinal products that increase serum sodium concentration, is not recommended during initial treatment or for other patients with very low baseline serum sodium concentrations (see section 4.5).</p><p><strong>Diabetes mellitus</strong><br />Diabetic patients with an elevated glucose concentration (e.g., in excess of 300 mg/dl) may present with pseudo-hyponatremia. This condition should be excluded prior and during treatment with tolvaptan. Tolvaptan may cause hyperglycemia (see section 4.8). Therefore, diabetic patients treated with tolvaptan should be managed cautiously. In particular this applies to patients with inadequately controlled type II diabetes.</p><p><strong>Idiosyncratic hepatic toxicity</strong><br />Liver injury induced by tolvaptan was observed in clinical trials investigating a different indication (autosomal dominant polycystic kidney disease [ADPKD]) with long-term use of tolvaptan at higher doses than for the approved indication (see section 4.8).</p><p>In post-marketing experience with tolvaptan in ADPKD, acute liver failure requiring liver transplantation has been reported (see section 4.8).</p><p>In these clinical trials, clinically significant increases (greater than 3 &times; Upper Limit of Normal [ULN]) in serum alanine aminotransferase (ALT), along with clinically significant increases (greater than 2 &times; ULN) in serum total bilirubin were observed in 3 patients treated with tolvaptan. In addition, an increased incidence of significant elevations of ALT was observed in patients treated with tolvaptan [4.4 % (42/958)] compared to those receiving placebo [1.0 % (5/484)]. Elevation (&gt; 3 &times; ULN) of serum aspartate aminotransferase (AST) was observed in 3.1 % (30/958) of patients on tolvaptan and 0.8 % (4/484) patients on placebo. Most of the liver enzyme abnormalities were observed during the first 18 months of treatment. The elevations gradually improved after discontinuation of tolvaptan. These findings may suggest that tolvaptan has the potential to cause irreversible and potentially fatal liver injury.</p><p>In a post-authorisation safety study of tolvaptan in hyponatremia secondary to SIADH, several cases of hepatic disorders and elevated transaminases were observed (see section 4.8).</p><p>Liver function tests must be promptly performed in patients taking tolvaptan who report symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice. If liver injury is suspected, tolvaptan must be promptly discontinued, appropriate treatment has to be instituted, and investigations have to be performed to determine the probable cause. Tolvaptan must not be re-initiated in patients unless the cause for the observed liver injury is definitively established to be unrelated to treatment with tolvaptan.</p><p><strong>Anaphylaxis</strong><br />In post-marketing experience, anaphylaxis (including anaphylactic shock and generalised rash) has been reported very rarely following administration of tolvaptan. Patients have to be carefully monitored during treatment. Patients with known hypersensitivity reactions to benzazepine or benzazepine derivatives (e.g., benazepril, conivaptan, fenoldopam mesylate or mirtazapine) may be at risk for hypersensitivity reaction to tolvaptan (see section 4.3 Contraindications).</p><p>If an anaphylactic reaction or other serious allergic reactions occur, administration of tolvaptan must be discontinued immediately and appropriate therapy initiated. Since hypersensitivity is a contraindication (see section 4.3) treatment must never be restarted after an anaphylactic reaction or other serious allergic reactions.</p><p><strong>Salitav contains lactose and sodium</strong><br />Salitav contains lactose. Each tablet of Salitav 15 mg Tablets contains 28 mg lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>Salitav contains sodium. Each tablet of Salitav 15 mg Tablets contains 0.46 mg sodium. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Co-administration with other treatments for hyponatremia and medicinal products that increase serum sodium concentration</em></strong><br />There is no experience from controlled clinical trials with concomitant use of tolvaptan and other treatments for hyponatremia such as hypertonic sodium chloride solution, oral sodium formulations, and medicinal products that increase serum sodium concentration. Medicinal products with high sodium content such as effervescent analgesic preparations and certain sodium containing treatments for dyspepsia may also increase serum sodium concentration. Concomitant use of tolvaptan with other treatments for hyponatremia or other medicinal products that increase serum sodium concentration may result in a higher risk for developing rapid correction of serum sodium (see section 4.4) and is therefore not recommended during initial treatment or for other patients with very low baseline serum sodium concentrations where rapid correction may represent a risk for osmotic demyelination (see section 4.4).</p><p><strong><em>Effect of other medicinal products on the pharmacokinetics of tolvaptan</em></strong><br /><strong>CYP3A4 inhibitors</strong><br />Tolvaptan plasma concentrations have been increased by up to 5.4-fold area under time-concentration curve (AUC) after the administration of strong CYP3A4 inhibitors. Caution should be exercised in co-administering CYP3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics, diltiazem) with tolvaptan. Co-administration of grapefruit juice and tolvaptan resulted in a 1.8-fold increase in exposure to tolvaptan. Patients taking tolvaptan should avoid ingesting grapefruit juice.</p><p><strong>CYP3A4 inducers</strong><br />Tolvaptan plasma concentrations have been decreased by up to 87 % (AUC) after the administration of CYP3A4 inducers. Caution has to be exercised in co-administering CYP3A4 inducers (e.g., rifampicin, barbiturates) with tolvaptan.</p><p><strong><em>Effect of tolvaptan on the pharmacokinetics of other products</em></strong><br /><strong>CYP3A4 substrates</strong><br />In healthy subjects, tolvaptan, a CYP3A4 substrate, had no effect on the plasma concentrations of some other CYP3A4 substrates (e.g., warfarin or amiodarone). Tolvaptan increased plasma levels of lovastatin by 1.3-fold to 1.5-fold. Even though this increase has no clinical relevance, it indicates tolvaptan can potentially increase exposure to CYP3A4 substrates.</p><p><strong><em>Transporter substrates</em><br />P-glycoprotein substrates</strong><br /><em>In-vitro </em>studies indicate that tolvaptan is a substrate and competitive inhibitor of P-glycoprotein (P-gp). Steady state digoxin concentrations were increased (1.3-fold in maximum observed plasma concentration [Cmax] and 1.2-fold in area under the plasma concentration-time curve over the dosing interval [AUC&tau;]) when co-administered with multiple once daily 60 mg doses of tolvaptan. Patients receiving digoxin or other narrow therapeutic index P-gp substrates (e.g., dabigatran etexilate) must therefore be managed cautiously and evaluated for excessive effects when treated with tolvaptan.</p><p><strong>BCRP and OCT1</strong><br />Co-administration of tolvaptan (90 mg) with rosuvastatin (5 mg), a BCRP substrate, increased rosuvastatin C<sub>max</sub> and AUC<sub>t</sub> of 54 % and 69 %, respectively. If BCRP substrates (e.g., sulfasalazine) are co-administered with tolvaptan, patients must be managed cautiously and evaluated for excessive effects of these medicinal products.</p><p>If OCT1 substrates (e.g., metformin) are co-administered with tolvaptan, patients must be managed cautiously and evaluated for excessive effects of these medicinal products.</p><p><strong>Diuretics</strong><br />While there does not appear to be a synergistic or additive effect of concomitant use of tolvaptan with loop and thiazide diuretics, each class of agent has the potential to lead to severe dehydration, which constitutes a risk factor for renal dysfunction. If dehydration or renal dysfunction becomes evident, take appropriate action which may include the need to interrupt or reduce doses of tolvaptan and/or diuretics, increase fluid intake, evaluate and address other potential causes of renal dysfunction or dehydration.</p><p><strong>Co-administration with vasopressin analogues</strong><br />In addition to its renal aquaretic effect, tolvaptan is capable of blocking vascular vasopressin V2-receptors involved in the release of coagulation factors (e.g., von Willebrand factor) from endothelial cells. Therefore, the effect of vasopressin analogues such as desmopressin may be attenuated in patients using such analogues to prevent or control bleeding when co-administered with tolvaptan.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong><br />There are no or limited amount of data from the use of tolvaptan in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Salitav is contraindicated during pregnancy (see section 4.3). Women of childbearing potential have to use effective contraception during tolvaptan treatment.</p><p><strong>Breast-feeding</strong><br />It is unknown whether tolvaptan is excreted in human milk. Available pharmacodynamic/toxicological data in animals have shown excretion of tolvaptan in breast milk (for details see 5.3). The potential risk for humans is unknown. Salitav is contraindicated during breast-feeding (see section 4.3).</p><p><strong>Fertility</strong><br />Studies in animals showed effects on fertility (see section 5.3). The potential risk for humans is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tolvaptan has no or negligible influence on the ability to drive or use machines. However, when driving or using machines it should be taken into account that occasionally dizziness, asthenia or syncope may occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Summary of the safety profile</strong><br />The adverse reaction profile of tolvaptan in SIADH is based on a clinical trials database of 3,294 tolvaptan-treated patients and is consistent with the pharmacology of the active substance. The pharmaco-dynamically predictable and most commonly reported adverse reactions are thirst, dry mouth and pollakiuria occurring in approximately 18 %, 9 % and 6 % of patients.</p><p><strong>Tabulated list of adverse reactions</strong><br />The frequencies of the adverse reactions from clinical trials correspond with very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>The frequency of adverse reactions reported during post-marketing use cannot be determined as they are derived from spontaneous reports. Consequently, the frequency of these adverse reactions is qualified as &quot;not known&quot;.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>System Organ Class </strong></p></td><td colspan="4"><p><strong>Frequency </strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p>Very common</p></td><td><p>Common</p></td><td><p>Uncommon</p></td><td><p>Not known</p></td></tr><tr><td><p><strong>Immune system disorders </strong></p><p><strong>&nbsp;</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Anaphylactic shock,</p><p>Generalised rash</p></td></tr><tr><td><p><strong>Metabolism and nutrition disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>Polydipsia,</p><p>Dehydration,</p><p>Hyperkalemia,</p><p>Hyperglycemia,</p><p>Hypoglycemia<sup>1</sup>,</p><p>Hypernatremia<sup>1</sup>,</p><p>Hyperuricemia<sup>1</sup>,</p><p>Decreased appetite</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Nervous system disorders </strong></p><p><strong>&nbsp;</strong></p></td><td><p>&nbsp;</p></td><td><p>Syncope<sup>1</sup>,</p><p>Headache<sup>1</sup>,</p><p>Dizziness<sup>1</sup></p></td><td><p>Dysgeusia</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Vascular disorders </strong></p><p><strong>&nbsp;</strong></p></td><td><p>&nbsp;</p></td><td><p>Orthostatic hypotension</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Gastrointestinal disorders </strong></p><p><strong>&nbsp;</strong></p></td><td><p>Nausea</p><p>&nbsp;</p></td><td><p>Constipation,</p><p>Diarrhoea<sup>1</sup>,</p><p>Dry mouth</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Skin and subcutaneous tissue disorders </strong></p></td><td><p>&nbsp;</p></td><td><p>Ecchymosis,</p><p>Pruritus</p></td><td><p>Pruritic rash<sup>1</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Renal and urinary disorders </strong></p></td><td><p>&nbsp;</p></td><td><p>Pollakiuria,</p><p>Polyuria</p></td><td><p>Renal impairment</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>General disorders and administration site conditions </strong></p></td><td><p>Thirst</p></td><td><p>Asthenia,</p><p>Pyrexia,</p><p>Malaise<sup>1 </sup></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Hepatobiliary disorders </strong></p><p><strong>&nbsp;</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Hepatic disorders<sup>2</sup></p><p>Acute hepatic failure<sup>3</sup></p></td></tr><tr><td><p><strong>Investigations </strong></p><p><strong>&nbsp;</strong></p></td><td><p>&nbsp;</p></td><td><p>Blood urine present<sup>1</sup>,</p><p>Alanine aminotransferase increased (see section 4.4)<sup>1</sup>,</p><p>Aspartate aminotransferase increased (see section 4.4)<sup>1</sup>,</p><p>Blood creatinine increased</p></td><td><p>Bilirubin increased (see section 4.4)<sup> 1</sup></p></td><td><p>Elevated transaminases<sup>2</sup></p></td></tr><tr><td><p><strong>Surgical and medical procedures </strong></p><p><strong>&nbsp;</strong></p></td><td><p>Rapid correction of hyponatremia, sometimes leading to neurological symptoms</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p><sup>1</sup> Observed in clinical trials investigating other indications</p><p><sup>2</sup> From post-authorisation safety study in hyponatremia secondary to SIADH</p><p><sup>3</sup> Observed in post-marketing with tolvaptan in ADPKD. Liver transplantation was necessary.</p><p><strong>Description of selected adverse reactions</strong><br /><u>Rapid correction of hyponatremia</u><br />In a post-authorisation safety study of tolvaptan in hyponatremia secondary to SIADH, including a high proportion of patients with tumours (especially Small Cell Lung Cancer), patients with low baseline serum sodium as well as patients with concomitant use of diuretics and/or sodium chloride solution the incidence of rapid correction of hyponatremia was found to be higher than in clinical trials.</p><p><strong>Reporting of suspected adverse reactions</strong><br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single doses up to 480 mg and multiple doses up to 300 mg per day for 5 days have been well tolerated in clinical trials in healthy volunteers. There is no specific antidote for tolvaptan intoxication. The signs and symptoms of an acute overdose can be anticipated to be those of excessive pharmacologic effect: a rise in serum sodium concentration, polyuria, thirst and dehydration/hypovolemia (profuse and prolonged aquaresis).</p><p>In patients with suspected tolvaptan overdose, assessment of vital signs, electrolyte concentrations, ECG and fluid status is recommended. Appropriate replacement of water and/or electrolytes must continue until aquaresis abates. Dialysis may not be effective in removing tolvaptan because of its high binding affinity for human plasma protein (&gt; 98 %).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Diuretics, vasopressin antagonists, ATC code: C03XA01.</p><p><strong>Mechanism of action</strong><br />Tolvaptan is a selective vasopressin V2-receptor antagonist that specifically blocks the binding of arginine vasopressin (AVP) at the V2-receptor of the distal portions of the nephron. Tolvaptan affinity for the human V2-receptor is 1.8-times that of native AVP.</p><p>In healthy adult subjects, oral administration of 7.5 mg to 120 mg doses of tolvaptan produced an increase in urine excretion rate within 2 hours of dosing. Following single oral doses of 7.5 mg to 60 mg, 24-hour urine volume increased dose dependently with daily volumes ranging from 3 to 9 litres. For all doses, urine excretion rates returned to baseline levels after 24 hours. For single doses 60 mg to 480 mg, a mean of about 7 litres was excreted during 0 to 12 hours, independent of dose. Markedly higher doses of tolvaptan produce more sustained responses without affecting the magnitude of excretion, as active concentrations of tolvaptan are present for longer periods of time.</p><p><strong>Clinical efficacy and safety</strong><br /><u>Hyponatremia</u><br />In 2 pivotal, double-blind, placebo-controlled, clinical trials, a total of 424 patients with euvolemic or hypervolemic hyponatremia (serum sodium &lt; 135 mEq/L) due to a variety of underlying causes (heart failure [HF], liver cirrhosis, SIADH and others) were treated for 30 days with tolvaptan (n = 216) or placebo (n = 208) at an initial dose of 15 mg/day. The dose could be increased to 30 mg/day and 60 mg/day depending on response using a 3-day titration scheme. The mean serum sodium concentration at trial entry was 129 mEq/L (range 114 mEq/L to 136 mEq/L).</p><p>The primary endpoint for these trials was the average daily AUC for change in serum sodium from baseline to Day 4 and baseline to Day 30. Tolvaptan was superior to placebo (p &lt; 0.0001) for both periods in both studies. This effect was seen in all patients, the severe (serum sodium: &lt; 130 mEq/L) and mild (serum sodium: 130 mEq/L to &lt; 135 mEq/L) subsets and for all disease aetiology subsets (e.g., HF, cirrhosis, SIADH/other). At 7 days after discontinuing treatment, sodium values decreased to levels of placebo treated patients.</p><p>Following 3 days of treatment, the pooled analysis of the two trials revealed 5-fold more tolvaptan than placebo patients achieved normalisation of serum sodium concentrations (49 % <em>vs. </em>11 %). This effect continued as on Day 30, when more tolvaptan than placebo patients still had normal concentrations (60 % <em>vs. </em>27 %). These responses were seen in patients independent of the underlying disease. The results of self-assessed health status using the SF-12 Health Survey for the mental scores showed statistically significant and clinically relevant improvements for tolvaptan treatment compared to placebo.</p><p>Data on the long-term safety and efficacy of tolvaptan were assessed for up to 106 weeks in a clinical trial in patients (any aetiology) who had previously completed one of the pivotal hyponatremia trials. A total of 111 patients started tolvaptan treatment in an open-label, extension trial, regardless of their previous randomisation. Improvements in serum sodium levels were observed as early as the first day after dosing and continued for on-treatment assessments up to Week 106. When treatment was discontinued, serum sodium concentrations decreased to approximately baseline values, despite the reinstatement of standard care therapy.</p><p>In a pilot, randomised (1:1:1), double-blind trial in 30 patients with hyponatremia secondary to SIADH, the pharmacodynamics of tolvaptan following single doses of 3.75 mg, 7.5 mg and 15 mg were assessed. Results were highly variable with large overlap between dose groups; changes were not significantly correlated with tolvaptan exposure. Mean maximal changes in serum sodium were highest following the 15 mg dose (7.9 mmol/L) but median maximal changes were highest for the 7.5 mg dose (6.0 mmol/L). Individual maximal increases in serum sodium were negatively correlated with fluid balance; mean change in fluid balance showed a dose dependent decrease. Mean change from baseline in cumulative urine volume and urine excretion rates was 2-fold higher for the 15 mg dose compared to the 7.5 mg and 3.75 mg doses, which showed similar responses.</p><p><u>Heart failure</u><br />EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan) was a long-term outcome, double-blind, controlled clinical trial in patients hospitalised with worsening HF and signs and symptoms of volume overload. In the long-term outcome trial, a total of 2,072 patients received 30 mg tolvaptan with standard of care (SC) and 2,061 received placebo with SC. The primary objective of the study was to compare the effects of tolvaptan + SC with placebo + SC on the time to all-cause mortality and on the time to first occurrence of cardiovascular (CV) mortality or hospitalisation for HF. Tolvaptan treatment had no statistically significant favourable or unfavourable effects on overall survival or the combined endpoint of CV mortality or HF hospitalisation, and did not provide convincing evidence for clinically relevant benefit.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Absorption</em></strong><br />After oral administration, tolvaptan is rapidly absorbed with peak plasma concentrations occurring about 2 hours after dosing. The absolute bioavailability of tolvaptan is about 56 %. Co-administration of a 60 mg dose with a high-fat meal increases peak concentrations 1.4-fold with no change in AUC and no change in urine output. Following single oral doses of &ge; 300 mg, peak plasma concentrations appear to plateau, possibly due to saturation of absorption.</p><p><strong><em>Distribution</em></strong><br />Tolvaptan binds reversibly (98 %) to plasma proteins.</p><p><strong><em>Biotransformation</em></strong><br />Tolvaptan is extensively metabolised by the liver. Less than 1 % of intact active substance is excreted unchanged in the urine.</p><p>In-vitro studies indicate that tolvaptan or its oxobutyric metabolite may have the potential to inhibit OATP1B1, OAT3, BCRP and OCT1 transporters. Administration of rosuvastatin (OATP1B1 substrate) or furosemide (OAT3 substrate) to healthy subjects with elevated oxobutyric acid metabolite (inhibitor of OATP1B1 and OAT3) plasma concentrations did not meaningfully alter the pharmacokinetics of rosuvastatin or furosemide. See also section 4.5.</p><p><strong><em>Elimination</em></strong><br />The terminal elimination half-life is about 8 hours and steady-state concentrations of tolvaptan are obtained after the first dose.</p><p>Radio-labelled tolvaptan experiments showed that 40 % of the radioactivity was recovered in the urine and 59 % was recovered in the faeces where unchanged tolvaptan accounted for 32 % of radioactivity. Tolvaptan is only a minor component in plasma (3 %).</p><p><strong><em>Linearity</em></strong><br />Tolvaptan has linear pharmacokinetics for doses of 7.5 mg to 60 mg.</p><p><strong><em>Pharmacokinetics in special patient groups</em></strong><br /><strong>Age</strong><br />Clearance of tolvaptan is not significantly affected by age.</p><p><strong>Hepatic impairment</strong><br />The effect of mildly or moderately impaired hepatic function (Child-Pugh classes A and B) on the pharmacokinetics of tolvaptan was investigated in 87 patients with liver disease of various origins. No clinically significant changes have been seen in clearance for doses ranging from 5 mg to 60 mg. Very limited information is available in patients with severe hepatic impairment (Child-Pugh class C).</p><p>In a population pharmacokinetic analysis in patients with hepatic oedema, AUC of tolvaptan in severely (Child-Pugh class C) and mildly or moderately (Child-Pugh classes A and B) hepatic impaired patients were 3.1-times and 2.3-times higher than that in healthy subjects.</p><p><strong>Renal impairment</strong><br />In an analysis on population pharmacokinetics for patients with heart failure, tolvaptan concentrations of patients with mildly (creatinine clearance [Ccr] 50 ml/min to 80 ml/min) or moderately (Ccr 20 ml/min to 50 ml/min) impaired renal function were not significantly different to tolvaptan concentrations in patients with normal renal function (Ccr 80 ml/min to 150 ml/min). The efficacy and safety of tolvaptan in those with a creatinine clearance &lt; 10 ml/min has not been evaluated and is therefore unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity or carcinogenic potential.</p><p>Teratogenicity was noted in rabbits given 1,000 mg/kg/day (3.9-times the exposure in humans at the 60 mg dose, based on AUC). No teratogenic effects were seen in rabbits at 300 mg/kg/day (up to 1.9-times the exposure in humans at the 60 mg dose, based on AUC). In a peri-and post-natal study in rats, delayed ossification and reduced pup bodyweight were seen at the high dose of 1,000 mg/kg/day.</p><p>Two fertility studies in rats showed effects on the parental generation (decreased food consumption and body weight gain, salivation), but tolvaptan did not affect reproductive performance in males and there were no effects on the foetuses. In females, abnormal oestrus cycles were seen in both studies.</p><p>The no observed adverse effects level (NOAEL) for effects on reproduction in females (100 mg/kg/day) was about 6.7-times the exposure in humans at the 60 mg dose, based on AUC.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>Hypromellose</li><li>Lactose</li><li>Microcrystalline cellulose</li><li>Croscarmellose sodium</li><li>Maize starch</li><li>Colloidal silicone dioxide</li><li>Magnesium stearate.</li><li>FD&amp;C blue</li><li>Sodium lauryl sulfate</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from light and moisture.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/Aclar-aluminum blisters.</p><p>Pack size: 10 Tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. Box 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                16 December 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>